HORMONE ANALOGS WITH MULTIPLE CTP EXTENSIONS

Abstract: The invention provides peptide and protein pharmaceuticals with extended half-lives. The modified peptides and proteins of the invention contain at least two tandem extensions at their C-terminus comprising the carboxy terminal portion of human chorionic gonadotropin. These "CTP units" consist essentially of the native HCG- beta sequence from position 112-118 to position 145 or conservative modifications thereof.

Description: 5 HORMONE ANALOGS WITH MULTIPLE CTP EXTENSIONS Technical Field The invention relates to pharmaceutical- compounds modified so as to extend their .in vivo 10 " stability. More particularly, the invention concerns modifications- of peptides of pharmaceutical significance by tandem extension with the carboxy terminal peptide of human chorionic gonadotropin. 15 Background Art PCT application WO90/09800, published 7 September 1990, and incorporated herein by reference, describes various modifications of reproductive hormones. In addition, this publication discloses that protein 20. pharmaceuticals and hormones in general may be modified to extend their biological half-lives in vivo by ligation of the carboxy terminal portion of the HCG-β subunit or a variant thereof to the carboxy terminus. The PCT application disclosure does not specifically address 25 tandem extensions with multiple carboxy terminal portions (CTP) of the HCG-3 chain. The present invention is directed to such tandem extensions. Human chorionic gonadotropin (HCG) is one of at least four reproductive hormones in a family which also 30 includes follicle stimulating hormone, luteinizing hormone, and thyroid stimulating hormone. All of these hormones are comprised of o_ subunits which are identical among the group, and β subunits which differ according to the member of the family. The β subunit of HCG is - - r 5 substan ially larger than that of the remaining three hormones in that it contains approximately 34 additional amino acids at the C-terminus referred to herein as the carboxy terminal portion (CTP) which is considered responsible for the comparatively longer serum half-life of hCG as compared to other gonadotropins (Matzuk, M. et al., Endocrinol (1989) 126:376) . In the native hormone, this CTP extension contains four mucin-like 0-linked oligosaccharides. Disclosure of the Invention The invention provides modified peptides and proteins. ith extended biological half-lives which are characterized by .containing, at their carboxy terminus, tandem extensions of at least two CTP sequences. These extended proteins are useful for the same biological functions as their unmodified forms, but permit reduced dosages and other advantages due to their extended biological half-life. Thus, in one aspect, the invention is directed to a peptide or protein having a biological function in animals, wherein said peptide or protein is modified by a tandem extension at the C-terminus with at least two CTP units. In another aspect, the invention is directed to methods to extend the biological half-life of a peptide or a protein by providing such extensions. In other aspects, the invention is directed to recombinant materials and methods for the construction of the modified peptides of the invention, and to antibodies specifically immunoreactive with them. Brief Description of the Drawings Figures 1A-1C show the construction of vectors for the recombinant production of the β subunit of the hu an follicle stimulating hormone (FSH) containing one or two CTP units as a carboxy terminal extension. Figure 2 shows the enhancement of biological stability of FSH containing the two unit CTP C-terminal ' extension of its 0 subunit as compared bo wild- ype FSH. Modes of Carrying Out the Invention Any peptide or protein of biological significance is subject to modification according to the invention method. Included among such candidates for modification, therefore, are peptide hormones, such as the four human "reproductive" hormones set forth above, especially the. β -chains thereof; insulin; human growth hormone; enkephalin; ACTH; glucagon; and the like. Also useful as subjects for the modification of the invention are various growth factors such as insulin-like growth factors; epidermal growth factors; acidic and basic fibroblast growth factors; platelet-derived growth factors; the various colony stimulating factors, such as granulocyte CSF, macrophage-CSF, and the like; as well as the various cytokines such as IL-2, IL-3 and the plethora of additional interleukin proteins; the various inter ' ferons; tumor necrosis factor; and the like. Also ■ candidates for the method of the invention are short peptide sequences such as luteinizing hormone releasing hormone (LHRH) ; somatostatin; growth hormone releasing factor . (GHRF) ; and the endorphins. Additional protein medicaments such as alveolar surfactant proteins; natriuretic factors; adhesins; receptor peptides; receptor binding ligands in general; antibodies and fragments thereof; and any other useful peptide or protein with a desired biological function can be modified according to the methods described herein. As used herein, the "CTP unit" refers to an amino acid sequence found at the carboxy terminus of human chorionic gonadotropin which extends from amino acid 112-118 to residue 145 at the C-terminus. Thus, each CTP unit used to modify the carboxy terminus of the peptide or protein may independently contain 28-34 amino acids, depending on the N-terminus of the CTP. The "CTP unit" may correspond exactly to the native CTP sequence, or may be a variant wherein 1-5 of the amino acids contained in the sequence is substituted by a conservative analog of the native amino acid residue at that position, and wherein said substitutions taken cumulatively do not result in a substantial change in the stability conferring properties of the CTP unit. "Conservative analog" means, in the conventional sense, an analog wherein the residue substituted is of the same general amino acid category as that for which substitution is made. Amino acids have been classified into such groups, as is understood in the art, by, for example, Dayhoff, M. et al., Atlas of Protein Sequences and Structure (1972) 5.:89-99. In general, acidic amino acids fall into one group; basic amino acids into another; neutral hydrophilic amino acids-into another; and so forth. More specifically, amino acid residues can be generally subclassified into four- major subclasses as follows: Acidic: The residue has a negative charge due to loss of H ion at physiological pH and the residue is attracted by aqueous solution so as to seek the surface • positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium at physiological pH. Basic: The residue has a positive charge due to association with H ion at physiological pH and the residue is attracted by aqueous solution so as to seek the surface positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium at physiological pH. Neutral/nonpolar: The residues are not charged at physiological pH and the residue is repelled by aqueous solution so as to seek the inner positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium. These residues are also designated "hydrophobic" herein. Neutral/polar: The residues are not charged at physiological pH, but the residue is attracted by aqueous- solution so as to seek the outer positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium. It is understood, of course, that in a statistical collection of individual residue molecules some molecules will be charged, and some not, and there will be an attraction for or repulsion from an aqueous medium to a greater or lesser extent. To fit the definition of "charged, " a significant percentage (at least approximately 25%) of the individual molecules are charged at physiological pH. The degree of attraction or repulsion required -for classi ication as polar or nonpolar is arbitrary and, therefore, amino acids specifically contemplated by the invention have been classified as one or the other. Most amino acids not specifically named can be classified on the basis of known behavior. Amino acid residues can be further subclassified as cyclic or noncyclic, and aromatic or nonaromatic, self-explanatory classifications with respect to the side chain substituent groups of the residues, and as small or large. The residue is considered small if it contains a total of 4 carbon atoms or less, inclusive of the carboxyl carbon. Small residues are, of course, always nonaromatic. For the naturally occurring protein amino acids, subclassification according to the foregoing scheme is as follows. Acidic: Aspartic acid and Glutamic acid; Basic/noncyclic: Arginine, Lysine; Basic/cyclic: Histidine; Neutral/polar/small: Glycine, serine, cysteine; Neutral/nonpolar/small: Alanine; Neutral/polar/large/nonaromatic: Threonine, Asparagine, Glutamine; Neutral/polar/large aromatic: Tyrosine; Neutral/nonpolar/large/nonaromatic: Valine, Isoleucine, Leucine, Methionine; Neutral/nonpolar/large/aromatic: Phenylalanine, and Tryptophan. The gene-encoded secondary amino acid proline, although technically within the group neutral/nonpolar/ large/cyclic and nonaromatic, is a special case due to its known effects on the secondary conformation- of peptide chains, and is not, therefore, included in this defined group. If the modified peptides of the invention are constructed by modification of the gene, the CTP units will contain only gene encoded amino acid substitutions; however, if the CTP unit is synthesized by standard, for example, solid phase, peptide synthesis methods and ligated, for example, enzymatically, to the C-terminus of the acceptor peptide or protein, non-gene encoded amino acids, such as aminoisobutyric acid (Aib) , phenylglycine (Phg) , and the like can also be substituted for their analogous counterparts . These non-encoded amino acids also include, for example, beta-alanine (beta-Ala) , or other omega-amino acids, such as 3-amino propionic, 4-amino butyric and so forth, sarcosine (Sar) , ornithine (Orn) , citrulline (Cit) , t-butylalanine (t-BuA) , t-butylglycine (t-BuG) , N- methylisoleucme (N-Melle) , and cyclohexylalanine (Cha) , - - norleucine (Nle) , cysteic acid (Cya) 2-naphthylalanine (2-Nal) ; 1,-2, 3 ,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) ; mercaptovaleric acid (Mvl) ; /3-2-thienylalanine (Thi) ;.and methionine sulfoxide (MSO) . These also fall conveniently into particular categories. Based on the above definitions, Sar and beta-Ala and Aib are neutral/nonpolar/ small; t-BuA, t-BuG, N-Melle, Nle, Mvl and Cha are neutral/nonpolar/large/nonaromatic; Orn is basic/noncyclic; Cya is acidic; Cit, Acetyl Lys, and MSO are neutral/polar/ large/nonaromatic; and Phg, Nal , Thi and Tic are neutral/nonpolar/large/ aromatic. The various omega-amino acids are classified according to size as neutral/nonpolar/small (beta-Ala, i.e., 3-aminopropionic, 4-aminobutyric) or large (all others) . Other amino acid substitutions of those encoded in the gene can also be included in peptide compounds within the scope of the invention and can be classified within this general scheme according to their structure. It should be noted, of course, that the peptide or protein to which the tandem CTP residues is attached could also be in modified form from that ordinarily occurring biologically, as long as biological activity is retained. The modified peptides and proteins of the invention may be further modified in ways generally understood to derivatize amino acid sequences, such as phosphorylation, glycosylation, deglycosylation of ordinarily glycosylated forms, modification of the amino acid side chains (e.g., conversion of proline to hydroxyproline) and similar modifications analogous to those post-translational events which have been found to occur generally. Methods to construct the modified peptide and protein biologically active compounds of the invention are well known in the art. As set forth above, if only gene encoded amino acids are included, the most practical approach at present is to synthesize these materials recombinantly by modification of the DNA encoding the desired peptide. Techniques for site-directed mutagenesis, ligation of additional sequences, and construction of suitable expression systems are all, by now, well known in the art. The DNA encoding the CTP 844 - 9 - units to be added to the DNA encoding the desired peptide or protein are most conveniently constructed synthetically using standard solid phase- techniques, preferably to include restriction sites for ease of ligation, and coupled to the sequence encoding the candidate peptide o protein. If the DNA encoding the candidate peptide or protein is not already a part of an expression system containing suitable control elements for transcription and translation of the included coding sequence, the modified DNA coding sequences are provided with these features. As is well known, expression systems are now available compatible with a wide variety of hosts, including procaryotic hosts such as bacteria and eucaryotic hosts such as yeast, plant cells, insect cells, mammalian cells, avian cells, and the like. ' Alternatively, if the candidate biological is a short peptide or if enzymatic transfer of the subunit can be effected, the CTP units of the invention may be synthesized directly using m vitro solid phase peptide synthesis techniques and under these conditions, if desired, the CTP subunit may be modified by analogous amino acids which are not gene encoded. The resulting modified biologicals will contain- at least two CTP units in tandem at their C-terminus. Multiple CTP units containing three or more CTP units are also envisioned and included within the scope of the present invention. As noted above, the CTP units conjugated to the C-terminus in tandem need not be identical with each other. They may vary in length with respect to the N-terminal starting amino acid (position 112-118 of the human chorionic gonadotropin β subunit) and the amino acid substitutions for the native residues, if any, may vary from unit to unit in the tandem sequences included. Coupled Forms of the Invention Proteins As is generally known in the art, the modified peptides and proteins of the invention may be coupled to labels, drugs, targeting agents, carriers, solid supports, and the like, depending on the ^ desired application. The labeled forms of the modified biologicals may be used to track their metabolic fate; suitable labels for this purpose include, especially, radioisotope labels such as iodine 131, technetium 99, indium 111, and the like. The labels may also be used to mediate detection of the modified proteins or peptides in assay systems; in this instance, radioisotopes may also be used as well as enzyme labels, fluorescent labels, chromogenic labels, and the like. The use of such labels is particularly helpful if the peptide or protein is itself a targeting agent such as an antibody or a receptor ligand. Conversely, if the modified peptide or protein is a targeting ligand, primarily, and is relatively free of metabolism-altering activity, the modified compound of the invention may be conjugated to an appropriate drug, such as an antimflammatory drug, an antibiotic, a toxin, and the like. The modified compounds of the invention may also be coupled to carriers to enhance their immunogenicity in the preparation of antibodies specifically immunoreactive with these new modified forms. Suitable carriers for this purpose include keyhole limpet hemocyanin (KLH) , bovine serum albumin (BSA) and diphtheria toxoid, and the like. Standard. coupling techniques for linking the modified peptides of the invention to carriers, including the use of bifunctional linkers, can be employed. Similar linking techniques, along with others, may be employed to couple the modified peptides and proteins of the invention to solid supports. When coupled, these modified peptides and proteins can then be used as affinity reagents for the separation of desired components with which specific reaction is exhibited. Finally, the modified peptides and proteins of the invention may be used to generate antibodies specifically immunoreactive with these new compounds. These antibodies are useful in a variety of diagnostic and therapeutic applications, depending on the nature of the biological activity of the unmodified peptide or protein. The modified peptides or proteins of the invention are formulated and administered using methods comparable to those known for the unmodified peptide or protein corresponding to the modified form. Thus, formulation and administration methods will vary according to the candidate unmodified form. However, the dosage level and frequency of administration may be reduced as compared to the unmodified form in view of the extended biological half life of the modified peptide or protein. The following examples are intended to illustrate but not to limit the invention. Example 1 Preparation of Human β Subunit with Two CTP Unit Tandem Extensions Figures 1A and IB show the construction of an expression vector wherein the β-chain of human FSH is modified to include two CTP units. As shown in Figure IB, the Hindlll site at the 3' -terminus of the human FSH- β subunit, extended by one CTP unit is used to couple the CTP unit from the 3' terminus of the human HCG-jS gene to obtain the extended β subunit. The hFSH-/3 (CTP) 2 gene is then ligated into the expression vector pM 2 to obtain an expression system capable of producing the extended form of the FSH-iS chain in mammalian cells. The construction of the host expression vectors is described by Matzuk, M.M. et al., Proc Natl Acad Sci USA (1987) £4:6354-6358; Matzuk, M.M. et al., J Cell Biol (1988) 106:1049-1059. In more detail, to create hFSHS chimera bearing a single unit of the O-linked terminal region of hCG/3 subunit (hFSH5 (CTP) ) a Hindlll site was created in the stop codon of hFSH3 gene at codon 111 and in the hCGJ gene at codon 118 (Figure 1A) . The Hindlll-Hindlll fragment from the hFSHjS gene was ligated in frame to the CGβ BamHI-Hindlll fragment. This chimera (hFSH3(CTP) ) contained a ser 118 to Ala 118 change at the ligation point, which was corrected by oligonucleotide-directed mutagenesis. The chimera containing two tandem CTP repeats (hFSHjS (CTP) 2 was constructed by creating a new Hindlll site in the stop codon of the hFSHø(CTP) chimera (Figure IB) . The Hindlll-Hindlll fragment was ligated to the BamHI-Hindlll fragment from hCGβ . The generated ala codon can be reconverted to a serine codon as described above. To insert hFSHβ(CTP) or hFSH/?(CTP) 2 genes into the eucaryotic expression vector pM 2 , the Hindlll sites at the 5' ends were converted to BamHI sites using Klenow and BamHI oligonucleotide linker (Figure 1C) , and the BamHI-Ba HI fragments containing the hFSHøCTP or hFSHjS(CTP)2 genes were inserted into the BamHI site in pM . The correct orientation was confirmed by restriction enzyme analysis and the entire sequence of exon III was sequenced to confirm the specificity of the mutagenesis. Example 2 Effect of CTP Tandem Extensions The human FSH containing the β subunit extended by two CTP units prepared as set forth in Example 1 above was injected into rats. 24 Sprague-Dawley female rats were used in the study. 12 rats were each injected with 10 IU unmodified FSH formulated in MEM medium; 12 rats were injected with 10 IU FSH comprising hFSHβ(CTP) 2 formulated in MEM medium. Serum was withdrawn immediately and several times during the first hour, and then after 2, 4 and 8 hours. The serum was assayed using standard radioimmunoassay techniques for FSH hormone. The results are shown in Figure 2. As there shown, while the amount of unmodified FSH in the serum declined from about 0.5 IU/ml to less than 0.05 IU/ml over an 8 hour period, the modified FSH of the invention containing two CTP units remains substantially unchanged over this time period declining from about 0.8 IU/ml to about 0.5 IU/ml.

Claims: 844 -14- Claims 1. A modified peptide or protein, said modified peptide or protein comprising a peptide or protein having a biological activity extended at its C- teπninus by two or more tandem CTP units. ■ 2. The modified peptide or protein of claim 1 wherein said CTP unit consists essentially of the amino acid sequence found natively at positions 112-118 to position 145 of the β subunit of human chorionic gonadotropin. 3. - The modified peptide or protein of claim 1 wherein at least one CTP unit contains at least one conservative amino acid substitution with respect to the native amino acid sequence at positions 112-118 to 145 of the β subunit of human chorionic gonadotropin. 4. A DNA sequence encoding the modified peptide or protein of claim 1. 5. A recombinant expression system capable of producing, when contained in a recombinant host cell, a modified peptide or protein, said modified peptide or protein comprising a peptide or protein having a biological activity extended at its C-terminus by two or more tandem CTP units, said expression system comprising a DNA encoding said modified peptide or protein operably linked to control sequences to effect its expression. 6. The recombinant host cells transfected or transformed with the expression system of claim 5. 7. A method to produce a modified peptide or protein said modified peptide or protein comprising a peptide or protein having a biological activity extended at its C-terminus by two or more tandem CTP units which method comprises culturing the cells of claims of claim 6 under conditions wherein said encoding DNA is expressed; and recovering said modified peptide or protein from the culture. 8. A method to extend the biological half-life of a biologically active peptide or protein which method comprises extending the amino acid sequence of said peptide or protein by at least two tandem CTP units. 9. The modified peptide or protein of claim 1 wherein said modified peptide or protein is further coupled to additional substituents which do not alter the amino acid sequence. 10. The modified peptide or protein of claim 9 wherein said additional substituent is selected from the group consisting of a solid support, a label, a drug, a saccharide and an immunogenicity conferring carrier. 11. Antibodies specifically immunoreactive with the modified peptide or protein of claim 1.

Inventors: BOIME IRVING, BOIME, IRVING
Applicants: UNIV WASHINGTON, WASHINGTON UNIVERSITY
Application year: 1992
Main classification: A61K37
IPC codes: A61K38, A61K39, C07K14, C07K16, C07K19, C12N1, C12N5, C12N15, C12P21, C12R1